LifeVantage Corporation — Form 10-Q Summary
Period clarification: The filing is for the quarter ended March 31, 2022 (fiscal 2022 third quarter), not calendar 2021 Q3 as stated in the request. The financial statements are unaudited; amounts below are in U.S. dollars unless indicated.
Business context and reporting period
LifeVantage sells nutrigenomics, dietary supplement, personal care, and related products through independent distributors and direct sales across the Americas and Asia/Pacific & Europe. The filing reports the three and nine months ended March 31, 2022, compared with the same periods in 2021.
Key financial results
| Metric | Q3 FY2022 | Q3 FY2021 | Nine months FY2022 | Nine months FY2021 |
|---|---|---|---|---|
| Revenue | $50.0 million | $51.6 million | $155.4 million | $165.4 million |
| Gross profit / margin | $40.3 million / 80.7% | $42.8 million / 82.9% | $126.7 million / 81.5% | $137.0 million / 82.8% |
| Operating income | $1.8 million | $2.1 million | $6.1 million | $11.0 million |
| Net income | $1.1 million | $1.7 million | $4.5 million | $8.0 million |
| Diluted EPS | $0.09 | $0.12 | $0.34 | $0.55 |
| Operating cash flow | Not separately provided | Not separately provided | $5.2 million | $7.9 million |
Q3 commissions and incentives were $23.2 million (46.4% of revenue), versus $25.2 million (48.8%); SG&A was $15.3 million (30.6%), versus $15.5 million (30.1%). Interest expense was minimal. The filing reports no remaining term-loan balance; it describes a $5.0 million revolving facility but does not clearly state whether any revolver borrowings were outstanding.
At March 31, 2022, cash was $17.8 million, working capital was $21.5 million, total assets were $72.2 million, and total liabilities were $38.2 million. Cash declined $5.4 million from June 30, 2021. Nine-month investing cash use was $1.3 million, financing cash use was $8.1 million, and foreign-currency effects reduced cash by $1.2 million. The company repurchased $8.4 million of stock during the nine-month period.
Changes versus the prior comparable period
- Revenue fell 3.0% in Q3 and 6.0% for the nine-month period. The Americas declined 8.2% and 10.6%, respectively; Asia/Pacific & Europe grew 9.3% and 4.9%.
- Active accounts declined 6.5% year over year to 157,000, including a 9.5% decline in active customers. Active distributors decreased 1.6%. Americas active accounts fell 10.7%, while Asia/Pacific & Europe rose 4.3%.
- Gross margin contracted, primarily from higher inventory obsolescence and shipping costs and changes in geographic and product mix. Nine-month obsolete and slow-moving inventory expense was $1.0 million, versus $0.3 million.
- Nine-month operating income and net income decreased despite lower commissions and SG&A in dollars. Management attributed higher SG&A as a share of revenue in part to increased event, travel, and legal expenses.
- Foreign exchange reduced revenue by approximately $1.2 million in Q3 and $2.4 million for nine months. Japan revenue was pressured by yen weakness and pandemic-related limits on in-person recruiting.
Outlook, risks, contingencies, and unusual items
- Management believes cash and ongoing operating cash flow will cover requirements for at least the next 12 months. It expects SG&A as a percentage of revenue to remain steady for the rest of fiscal 2022; it also expects some fluctuation in the effective tax rate.
- Management said the IC Bright product launch and further product and market expansion are intended to support growth. These are expectations, not guaranteed results.
- The company reported compliance with its credit-facility covenants at March 31, 2022 and anticipated continued compliance. The facility matures March 31, 2024, has a $5.0 million revolver, and includes financial and restrictive covenants.
- COVID-19, distributor recruitment and retention, supply-chain and inventory management, foreign exchange, product acceptance, direct-selling regulation, and legal proceedings remain risks. The company said it had experienced ongoing pandemic-related business and recruiting disruptions.
- In the Smith class action, the court denied plaintiffs’ motion for class certification on April 19, 2022, after the reporting date. The company had not accrued a loss, stating it did not consider liability probable or estimable; it noted an unfavorable resolution could be material.
- The board increased the share-repurchase authorization to $60 million in February 2022; $28.1 million remained at March 31, 2022. The filing reports no probable loss contingencies requiring accrual and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the reporting-period mapping: this is fiscal Q3 2022, quarter ended March 31, 2022—not 2021 Q3.
- Track whether revenue and active-account declines, particularly in the Americas, continue and whether Asia/Pacific & Europe growth offsets them.
- Monitor gross-margin pressures, inventory obsolescence, cash generation, and the use of cash for share repurchases.
- Review future disclosures for actual revolver borrowings, covenant headroom, and the impact of foreign exchange, especially the Japanese yen.
- Follow developments in the Smith litigation after the class-certification denial and any resulting financial or operational effects.